S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

KURA Kura Oncology Inc

14.00

-1.91 (-12.01%)

Pre Market

Last Updated: 21:07:40

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kathleen Ford

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Kura Oncology Charts.

Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Kura Oncology Charts.

Kura Oncology Inc News

Form 8-K - Current report
Thursday 21 November 2024 (12 hours ago) • Edgar (US Regulatory)

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Thursday 21 November 2024 (12 hours ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 20 November 2024 (2 days ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 19 November 2024 (3 days ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 8 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Kura Oncology Reports Third Quarter 2024 Financial Results
Friday 8 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Wednesday 6 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Kura Oncology to Report Third Quarter 2024 Financial Results
Thursday 31 October 2024 (3 weeks ago) • GlobeNewswire Inc.

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Thursday 24 October 2024 (4 weeks ago) • GlobeNewswire Inc.

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
Wednesday 23 October 2024 (4 weeks ago) • GlobeNewswire Inc.

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Tuesday 1 October 2024 (2 months ago) • GlobeNewswire Inc.

More Kura Oncology Inc News Articles

Invesco QQQ Trust Series 1

Newcrest Mining

JP Morgan Chase

Verizon Communications

National Australia Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions